{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:46Z","timestamp":1791563386422,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.mayocp.2014.08.021","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T02:13:44Z","timestamp":1416190424000},"page":"24-34","source":"Crossref","is-referenced-by-count":174,"title":["Effects of Coenzyme Q10 on Statin-Induced Myopathy"],"prefix":"10.1016","volume":"90","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Ursoniu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Glasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Dragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2014.08.021_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"3 suppl","key":"10.1016\/j.mayocp.2014.08.021_bib2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipid"},{"issue":"23","key":"10.1016\/j.mayocp.2014.08.021_bib3","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.021_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib5","first-page":"173","article-title":"Hypocalcemic myopathy secondary to hypoparathyroidism","volume":"111","author":"Policepatil","year":"2012","journal-title":"WMJ"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.021_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/rheumatology\/40.12.1417","article-title":"Hypoparathyroidism presenting as myopathy with raised creatine kinase","volume":"40","author":"Barber","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.021_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14310\/horm.2002.11154","article-title":"Hypoparathyroidism in a patient presenting with severe myopathy and skin rash: case report and review of the literature","volume":"4","author":"Syriou","year":"2005","journal-title":"Hormones (Athens)"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.021_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/S0004-282X2004000100028","article-title":"Hypocalcemic myopathy without tetany due to idiopathic hypoparathyroidism: case report","volume":"62","author":"Nora","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"issue":"25, suppl 2","key":"10.1016\/j.mayocp.2014.08.021_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.mayocp.2014.08.021_bib10","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2014.08.021_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2741\/4231","article-title":"Clinical applications of coenzyme Q10","volume":"19","author":"Garrido-Maraver","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/10408390902773037","article-title":"Coenzyme Q10 contents in foods and fortification strategies","volume":"50","author":"Pravst","year":"2010","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"7","key":"10.1016\/j.mayocp.2014.08.021_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF02535072","article-title":"Age-related changes in the lipid compositions of rat and human tissues","volume":"24","author":"Kalen","year":"1989","journal-title":"Lipids"},{"issue":"16","key":"10.1016\/j.mayocp.2014.08.021_bib14","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1089\/ars.2013.5406","article-title":"Ubiquinol-10 supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice","volume":"20","author":"Tian","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760290021306","article-title":"Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle","volume":"36","author":"Linnane","year":"2002","journal-title":"Free Radic Res"},{"issue":"22","key":"10.1016\/j.mayocp.2014.08.021_bib16","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib17","first-page":"324","article-title":"Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients","volume":"49","author":"Miyake","year":"1999","journal-title":"Arzneimittelforschung"},{"issue":"suppl","key":"10.1016\/j.mayocp.2014.08.021_bib18","doi-asserted-by":"crossref","first-page":"s187","DOI":"10.1016\/0098-2997(94)90028-0","article-title":"Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors","volume":"15","author":"Bargossi","year":"1994","journal-title":"Mol Aspects Med"},{"issue":"10","key":"10.1016\/j.mayocp.2014.08.021_bib19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2004.07.121","article-title":"Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction","volume":"94","author":"Silver","year":"2004","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.021_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.021_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"12","key":"10.1016\/j.mayocp.2014.08.021_bib22","doi-asserted-by":"crossref","first-page":"i","DOI":"10.3310\/hta3120","article-title":"Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses","volume":"3","author":"Moher","year":"1999","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.mayocp.2014.08.021_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.mayocp.2014.08.021_bib24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.021_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.021_bib27","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/j.atherosclerosis.2007.06.010","article-title":"Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study","volume":"195","author":"Mabuchi","year":"2007","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.mayocp.2014.08.021_bib28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.021_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand Cardiovasc J"},{"issue":"27","key":"10.1016\/j.mayocp.2014.08.021_bib30","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.2174\/1381612811319270014","article-title":"Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance","volume":"19","author":"Banach","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"11","key":"10.1016\/j.mayocp.2014.08.021_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archinternmed.2012.1240","article-title":"Statins and the risk of diabetes: the debate","volume":"172","author":"Katsiki","year":"2012","journal-title":"Arch Intern Med"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2014.08.021_bib32","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S1353-8020(09)70812-0","article-title":"Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease","volume":"15","author":"Beal","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.021_bib33","first-page":"483","article-title":"Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer","volume":"2","author":"Thibault","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.021_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.mayocp.2014.08.021_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/15216540701545991","article-title":"Functional connections and pathways of coenzyme Q10-inducible genes: an in-silico study","volume":"59","author":"Schmelzer","year":"2007","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.021_bib36","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.biocel.2004.11.017","article-title":"Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells","volume":"37","author":"Groneberg","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.021_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2478\/10004-1254-65-2014-2398","article-title":"Efficiency of hepatocyte pretreatment with coenzyme Q10 against statin toxicity","volume":"65","author":"Eghbal","year":"2014","journal-title":"Arh Hig Rada Toksikol"},{"key":"10.1016\/j.mayocp.2014.08.021_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-13-22","article-title":"Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet","volume":"13","author":"Jimenez-Santos","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2014.08.021_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1475-2891-12-142","article-title":"Effects of coenzyme Q10 supplementation (300 mg\/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial","volume":"12","author":"Lee","year":"2013","journal-title":"Nutr J"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.021_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/psm.2012.11.1991","article-title":"Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins","volume":"40","author":"Deichmann","year":"2012","journal-title":"Phys Sportsmed"},{"issue":"7","key":"10.1016\/j.mayocp.2014.08.021_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3949\/ccjm.77a.09078","article-title":"Coenzyme Q10: a therapy for hypertension and statin-induced myalgia?","volume":"77","author":"Wyman","year":"2010","journal-title":"Cleve Clin J Med"},{"issue":"9-10","key":"10.1016\/j.mayocp.2014.08.021_bib42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: a review of clinical and therapeutical implications","volume":"40","author":"Buhaescu","year":"2007","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.021_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2013.02.002","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design","volume":"7","author":"Parker","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.021_bib44","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961400799X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961400799X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T13:03:34Z","timestamp":1566047014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961400799X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S002561961400799X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2014.08.021","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}